Anti-ATM (phospho S1981) antibody [10H11.E12]
5
(2 Reviews)
|
(92 Publications)
Mouse Monoclonal ATM phospho S1981 antibody. Suitable for IHC-P, Flow Cyt (Intra), WB and reacts with Human samples. Cited in 92 publications.
View Alternative Names
Serine-protein kinase ATM, Ataxia telangiectasia mutated, A-T mutated, ATM
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ATM (phospho S1981) antibody [10H11.E12] (AB36810)
ab36810 staining human colon tissue. Staining is localized to the nucleus.
Left panel : with primary antibody at 4 μg/ml. Right panel : Isotype control.
Sections were stained using an automated system DAKO Autostainer Plus at room temperature. Sections were rehydrated and antigen retrieved with the DAKO 3-in-1 antigen retrieval buffer citrate pH 6.0 in a DAKO PT Link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 minutes. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 minutes and detected with Dako Envision Flex amplification kit for 30 minutes. Colorimetric detection was completed with diaminobenzidine for 5 minutes. Slides were counterstained with hematoxylin and coverslipped under DePeX.
Please note that for manual staining we recommend to optimize the primary antibody concentration and incubation time (overnight incubation), and amplification may be required.
- Flow Cyt (Intra)
Supplier Data
Flow Cytometry (Intracellular) - Anti-ATM (phospho S1981) antibody [10H11.E12] (AB36810)
Overlay histogram showing HeLa cells stained with ab36810 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab36810, 1μg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2μg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.
This antibody gave a positive signal in HeLa cells fixed with 4% paraformaldehyde (10 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.
- WB
Unknown
Western blot - Anti-ATM (phospho S1981) antibody [10H11.E12] (AB36810)
Lysate loading concentration : 40µg
All lanes:
Western blot - Anti-ATM (phospho S1981) antibody [10H11.E12] (ab36810) at 1/1000 dilution
Lane 1:
Control lane
Lane 2:
Irradiated Human fibroblasts (10 Gy gamma-irradiation)
Lane 3:
Molecular weight marker
Lane 4:
Peroxidated Human fibroblasts (300 µM hydrogen peroxide)
Lane 5:
Peroxidated Human fibroblasts (1 mM hydrogen peroxide)
Lane 6:
Peroxidated Human fibroblasts (10 mM hydrogen peroxide)
Predicted band size: 351 kDa
Observed band size: 370 kDa
true
- WB
Unknown
Western blot - Anti-ATM (phospho S1981) antibody [10H11.E12] (AB36810)
All lanes:
Western blot - Anti-ATM (phospho S1981) antibody [10H11.E12] (ab36810) at 10 µg/mL
Lane 1:
HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate at 20 µg
Lane 2:
Extract from patient with Ataxia-Telangiectasia whole cell lysate at 20 µg
Lane 3:
Irradiated HeLa Whole Cell Lysate at 20 µg
Secondary
All lanes:
Goat polyclonal to Mouse IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Predicted band size: 351 kDa
Observed band size: 100 kDa,110 kDa,145 kDa,200 kDa,370 kDa
true
Exposure time: 20min
- WB
CiteAb
Western blot - Anti-ATM (phospho S1981) antibody [10H11.E12] (AB36810)
Western Blotting using Anti-ATM (phospho S1981) antibody [10H11.E12], ab36810. Publication image from Gueven, N. et al., 2010, Mol Cancer, 20663147. Legend direct from paper.
p63 depletion attenuates ATM expression and ATM-dependent phosphorylation. (A) pSUPER-p63 RNAi attenuates ATM mRNA levels. HaCat cells were transfected with 1 µg pSUPER-CON or pSUPER-p63si vectors, and selected for geneticin resistance for 4 days. mRNA was extracted from surviving cells and real-time RT-PCR was used to quantitate changes in ATM mRNA expression. Data is represented as fold-change over empty vector control. (B) pSUPER-p63si inhibits ATM expression and p53 Serine-15 phosphorylation in HaCat cells. pSUPER-CON or pSUPER-p63si transfected HaCat cells were harvested after selection for 48 and 96 hours, and immunoblotted for the indicated proteins. (C) pSUPER-p63 RNAi inhibits HaCat cell proliferation. HaCaT cells were transfected with pSUPER-CON or pSUPER-p63si vectors, selected for geneticin resistance for 14 days, and surviving colonies were giemsa stained and counted. (D) siRNA-mediated p63 depletion attenuates ATM mRNA expression. HaCat cells untreated (NT) or treated with control siRNA or p63-targeted siRNA were harvested after 24 hrs or 48hrs and analysed by real-time RT-PCR for p63 and ATM mRNA expression. Data is normalised to β-actin and represented as fold-change over mRNA level in cells treated with control siRNA in particular time point. The data represent the average of three independent experiments + SD. The symbol asterisk denotes significant difference with p values < 0.05 determined by Mann-Whitney test, from the cells treated with control siRNA.
false
- WB
CiteAb
Western blot - Anti-ATM (phospho S1981) antibody [10H11.E12] (AB36810)
Western Blotting using Anti-ATM (phospho S1981) antibody [10H11.E12], ab36810. Publication image from Gueven, N. et al., 2010, Mol Cancer, 20663147. Legend direct from paper.
The ATM pathway is active in HaCaT cells. (A) Damage-induced p53 Serine-15 is mediated by ATM. HaCat cells were treated with DMSO carrier, 10 µM KU-55933 (ATM inhibitor) or 1 µM NU7441 (DNA-PK inhibitor) for 2 hours, then with 0.5 µM doxorubicin, and cells were harvested after 2hrs, or cells were treated with 20Jm2 UV radiation and harvested after 6hrs. Lysates were blotted for phosphoSerine-15 p53, phosphoSerine-392 p53, total p53 protein and p63, as indicated. (B) ATM inhibition blocks constitutive p53 Serine-15 phosphorylation. Cells were treated with DMSO carrier, 10 µM KU-55933 (ATM inhibitor) or 1 µM NU7441 (DNA-PK inhibitor) for 24 hrs, and lysates were immunoblotted for phosphoSerine-15 p53 and total p53 protein. (C) ATM inhibition blocks constitutive ATM-dependent phosphorylation. Cells were treated with DMSO carrier or 10 µM KU-55933 for 24 hrs, and lysates were immunoblotted for : phosphoSerine-15 p53, phosphoSerine-392 p53, total p53 protein, phosphoThreonine-68 Chk2, total Chk2 protein, phosphoSerine-1891 ATM, and total ATM protein. (D) siRNA-mediated ATM depletion blocks p53 Serine-15 phosphorylation. HaCat cells were treated with control siRNA or siRNA to ATM for 24, 48 or 96hrs, and cell lysates were blotted for ATM, phosphoSerine-15 p53, and total p53 protein.
false
Related conjugates and formulations (1)
-
Anti-ATM (phospho S1981) antibody [10H11.E12] - BSA and Azide free
Reactivity data
Product details
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
ATM acts as a coordinator in cellular response to DNA damage highly interacting with multiple components of the DNA repair machinery. It forms a complex with proteins like NBS1 and MRN complex facilitating repair by recruiting and activating other proteins involved in homologous recombination and non-homologous end joining pathways. ATM also modulates p53 activity a primary response factor in cellular stress management linking ATM to control of cell cycle arrest and apoptosis. This positions ATM as an integral part of maintaining cellular integrity in face of genomic insult.
Pathways
ATM integrates neatly within the DNA damage response and cell cycle control pathways. ATM's operative relationship with the MRN complex and its role in the PI3K-related protein kinase family helps initiate appropriate repair processes upon DNA damage detection. Additionally ATM regulates the activity of proteins such as Chk2 which further propagates signals to p53 influencing decisions between cell cycle arrest and apoptosis. These interactions link ATM closely to essential processes like DNA repair and cell survival highlighting its role in genomic maintenance.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (92)
Recent publications for all applications. Explore the full list and refine your search
Science advances 11:eado7660 PubMed40238889
2025
Applications
Unspecified application
Species
Unspecified reactive species
MedComm 5:e548 PubMed38645664
2024
Applications
Unspecified application
Species
Unspecified reactive species
Acta pharmacologica Sinica 45:1276-1286 PubMed38438580
2024
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 13:15171 PubMed37704669
2023
Applications
Unspecified application
Species
Unspecified reactive species
Science advances 9:eadf2860 PubMed37390209
2023
Applications
Unspecified application
Species
Unspecified reactive species
Cells 12: PubMed37296639
2023
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 24: PubMed37239999
2023
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 24: PubMed37108069
2023
Applications
Unspecified application
Species
Unspecified reactive species
Biology direct 17:40 PubMed36476259
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cancer research 82:4571-4585 PubMed36353752
2022
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com